Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-α for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis

Cancer

Volumn 88, Issue 9, 2000, Pages 1986-1991

  Chung, Young Hwa ^a   Song, Il Han ^a   Song, Byung Cheol ^a   Lee, Geun Chan ^a   Koh, Moon Soo ^a   Yoon, Hyum Ki ^a   Lee, Yung Sang ^a   Sung, Kyu Bo ^a   Suh, Dong Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Cisplatin; Hepatocellular carcinoma; Interferon ; Metastasis; Portal vein thrombosis

Indexed keywords

ALPHA INTERFERON; CISPLATIN; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ARTIFICIAL EMBOLISM; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL HEMORRHAGE; HEPATIC ARTERY; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; PALLIATIVE THERAPY; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; TUMOR THROMBUS; UREMIA; VOMITING;

EID: 0342314475     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000501)88:9<1986::AID-CNCR2>3.0.CO;2-I     Document Type: Article

References (29)

1. Okuda K. Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Cancer 1980;45:2663-9.
2. Lai CL, Lam KC, Wong KP, Wu PC, Todd D. Clinical features of hepatocellular carcinoma: review of 211 patients in Hong Kong. Cancer 1981;47:2746-55.
3. Ohnishi K, Tanabe Y, Ryu M, Isono K, Yamamoto Y, Usui S, et al. Prognosis of hepatocellular carcinoma smaller than 5 cm in relation to treatment: study of 100 patients. Hepatology 1987;7:1285-90.
4. Sutton FM, Russel NC, Guinee VF, Alpert E. Factor affecting the prognosis of primary liver carcinoma. J Clin Oncol 1988; 6:321-8.
5. Lai CL, Lau JYN, Wu PC, Hui WN, Lai ECS, Fan ST, et al. Subclinical hepatocellular carcinoma in Hong Kong Chinese. Oncology 1992;49:347-53.
6. Goldstein HM, Wallace S, Anderson JH, Bree RL, Gianturco C. Transcatheter occlusion of abdominal tumors. Radiology 1976;120:539-45.
7. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983;148:397-401.
8. Nakamura H, Hashimoto T, Oi H. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989;170:783-6.
9. Yamashita Y, Takahashi M, Koga Y, Saito R, Nanakawa S, Hatanaka Y, et al. Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion. Cancer 1991;67:385-91.
10. Bismuth H, Morino M, Sherlock D, Castaing D, Miglietta C, Cauquil P, et al. Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg 1992;163: 387-94.
11. Aoyama K, Tsukishiro T, Okada K, Tsuchida T, Aiba N, Nambu S, et al. Evaluation of transcatheter arterial embolization with epirubicin-lipiodol emulsion for hepatocellular carcinoma. Cancer Chemother Pharmacol 1992;31 (Suppl): S55-9.
12. Nakamura H, Mitani T, Murakami T, Hashimoto T, Tsuda K, Nakanishi K, et al. Five-year survival after transcatheter chemoembolization for hepatocellular carcinoma. Cancer Chemother Pharmacol 1994;33(Suppl):S89-92.
13. Sakurai M, Okamura J, Kuroda C. Transcatheter chemoembolization effective for treating hepatocellular carcinoma: a histopathologic study. Cancer 1984;54:387-92.
14. Hsu HC, Wei TC, Tsang YM, Wu MZ, Lin YH, Chunang SM. Histologic assessment of resected hepatocellular carcinoma after transcatheter hepatic arterial embolization. Cancer 1986;57:1184-91.
15. Olweny CH, Toya T, Katongole-Mbidof F, Mugerwa J, Kyalwazi SK, Cohen N. Treatment of hepatocellular carcinoma with Adriamycin. Cancer 1975;36:1250-7.
16. Falkson G, Moerterl CG, Lavin P, Pretorius FJ, Carbone PP. Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer 1978;42:2149-56.
17. Johnson PJ, Williams R, Thomas H. Sherlock S, Murry-Lyon IM. Induction of remission in hepatocellular carcinoma with Adriamycin. Lancet 1978;1:1005-9.
18. Friedman M. Primary hepatocellular carcinoma: present results and future prospects. Int I Radiat Oncol Biol Phys 1983;9:1841-50.
19. Kasugai H, Kojima J, Tatsuta M, Okuda S, Sasaki Y, Imaoka S, et al. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology 1989;97:965-71.
20. Imaoka S, Sasaki Y, Shibata T, Fujita M, Kasugai H, Kojima J, et al. A preoperative chemoembolization therapy using lipiodol, cisplatin and gelatin sponge. Cancer Chemother Pharmacol 1989;23(Suppl):S126-8.
21. Yodono H, Saito Y, Saikawa Y, Midorikawa H, Yokoyama Y, Takekawa S. Combination chemoembolization therapy for hepatocellular carcinoma: mainly, using cisplatin (CDDP). Cancer Chemother Pharmacol 1989;23(Suppl):S42-4.
22. Chakraborty PR, Ruiz-Opazo N, Shouval D, Sharfritz DA. Identification of integrated hepatitis B virus DNA and expression of viral RNA in HBsAg-producing human hepatocellular carcinoma. Nature 1980;286:531-3.
23. Dunk AA, Ikeda T, Pignatelli M, Thomas HC. Human lymphoblastoid interferon: in vitro and in vivo studies in hepatocellular carcinoma. J Hepatol 1986;2:419-29.
24. Sachs E, Di Bisceglie AM, Dusheiko GM, Song E, Lyons SF, Schuoub BD. Treatment of hepatocellular carcinoma with recombinant interferon: a pilot study. Br J Cancer 1985;52: 105-9.
25. Lai CL, Wu PC, Lok AS, Lin HJ, Ngan H, Lau JY, et al. Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Br J Cancer 1989;60:928-33.
26. Lai CL, Lau JYN, Wu PC, Ngan H, Chung HT, Mitchell SJ, et al. Recombinant interferon-a in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993; 17:389-94.
27. Kardinal CG, Moertel CG, Wieand HS, Schutt AJ, O'Connell MJ, Wright K, et al. Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma. Cancer 1993;71:2187-90.
28. Loehrer PJ, Einhorn LH. Drugs five year later: cisplatin. Ann Intern Med 1984;100:704-13.
29. Chung YH, Yang SK, Lee JS, Min YI, Lee MG, Sung KB, et al. Effects of cisplatin and Adriamycin in chemoembolization therapy for patients with unresectable hepatocellular carcinoma. Korean J Gastroenterol 1992;24:790-7.